1312 — Kontafarma China Holdings Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapValue Trap

Annual income statement for Kontafarma China Holdings, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.

	R2019 December 31st	2020 December 31st	R2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	HKAS	HKAS	HKAS	HKAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	921	1,009	803	894	809
Cost of Revenue
Gross Profit	497	556	396	506	471
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	812	978	824	989	838
Operating Profit	110	31.1	-20.9	-94.5	-28.7
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	79.1	-0.297	-54.5	-118	-43.9
Provision for Income Taxes
Net Income After Taxes	64.3	-20.1	-56.3	-110	-61.1
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	36.1	-267	-15	-41.5	-28.8
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	36.1	-267	-15	-41.5	-28.8
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.007	-0	-0.007	-0.016	0.003